Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082994" target="_blank" >RIV/00216224:14110/15:00082994 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/15:10294587 RIV/00064203:_____/15:10294587
Result on the web
<a href="http://dx.doi.org/10.2217/FON.14.240" target="_blank" >http://dx.doi.org/10.2217/FON.14.240</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/FON.14.240" target="_blank" >10.2217/FON.14.240</a>
Alternative languages
Result language
angličtina
Original language name
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data
Original language description
Aim: This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer. Patients & methods: Patients with KRASwildtype metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points. Results: A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7-11.8) and median overall survival was 28.4 months (95% CI: 26.2-30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%). Conclusion:This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future Oncology
ISSN
1479-6694
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
225-232
UT code for WoS article
000348055100007
EID of the result in the Scopus database
—